Iron Chelation in the Treatment of Cancer: A New Role for Deferasirox?

Efficacy and safety of deferasirox in myelodysplastic syndromes

(2013) Massimo Breccia et al.   ANNALS OF HEMATOLOGY

Novel Chelators for Cancer Treatment: Where Are We Now?

(2012) Angelica M. Merlot et al.   ANTIOXIDANTS & REDOX SIGNALING

Deferasirox (ICL670A) effectively inhibits oesophageal cancer growthin vitroandin vivo

(2012) SJ Ford et al.   BRITISH JOURNAL OF PHARMACOLOGY

The Iron Chelators Dp44mT and DFO Inhibit TGF-β-induced Epithelial-Mesenchymal Transition via Up-Regulation of N-Myc Downstream-regulated Gene 1 (NDRG1)

(2012) Zhiqiang Chen et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Deferasirox Reduces Serum Ferritin and Labile Plasma Iron in RBC Transfusion–Dependent Patients With Myelodysplastic Syndrome

(2012) Alan F. List et al.   JOURNAL OF CLINICAL ONCOLOGY

Iron mobilization using chelation and phlebotomy

(2012) Trond Peder Flaten et al.   JOURNAL OF TRACE ELEMENTS IN MEDICINE AND BIOLOGY

Iron Availability Increases the Pathogenic Potential of Salmonella Typhimurium and Other Enteric Pathogens at the Intestinal Epithelial Interface

(2012) Guus A. M. Kortman et al.   PLoS One

Luminal Iron Levels Govern Intestinal Tumorigenesis after Apc Loss In Vivo

(2012) Sorina Radulescu et al.   Cell Reports

The Oral Iron Chelator Deferasirox Induces Apoptosis in Myeloid Leukemia Cells by Targeting Caspase

(2011) Jung-Lim Kim et al.   ACTA HAEMATOLOGICA

Bp44mT: an orally active iron chelator of the thiosemicarbazone class with potent anti-tumour efficacy

(2011) Y Yu et al.   BRITISH JOURNAL OF PHARMACOLOGY

Wnt Inhibitor Screen Reveals Iron Dependence of  -Catenin Signaling in Cancers

(2011) S. Song et al.   CANCER RESEARCH

Deferasirox treatment of iron-overloaded chelation-naïve and prechelated patients with myelodysplastic syndromes in medical practice: results from the observational studies eXtend and eXjange

(2011) Norbert Gattermann et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Deferoxamine for Advanced Hepatocellular Carcinoma

(2011) Takahiro Yamasaki et al.   NEW ENGLAND JOURNAL OF MEDICINE

Deferasirox is a powerful NF- B inhibitor in myelodysplastic cells and in leukemia cell lines acting independently from cell iron deprivation by chelation and reactive oxygen species scavenging

(2010) E. Messa et al.   HAEMATOLOGICA

Changes in parameters of oxidative stress and free iron biomarkers during treatment with deferasirox in iron-overloaded patients with myelodysplastic syndromes

(2010) H. Ghoti et al.   HAEMATOLOGICA

Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study

(2010) Norbert Gattermann et al.   LEUKEMIA RESEARCH

Positive effects on hematopoiesis in patients with myelodysplastic syndrome receiving deferasirox as oral iron chelation therapy: A brief review

(2010) Roberto Guariglia et al.   LEUKEMIA RESEARCH

Ferroportin and Iron Regulation in Breast Cancer Progression and Prognosis

(2010) Z. K. Pinnix et al.   Science Translational Medicine

The oral iron chelator deferasirox represses signaling through the mTOR in myeloid leukemia cells by enhancing expression of REDD1

(2009) Junko H. Ohyashiki et al.   CANCER SCIENCE

Deferasirox Treatment Improved the Hemoglobin Level and Decreased Transfusion Requirements in Four Patients with the Myelodysplastic Syndrome and Primary Myelofibrosis

(2008) E. Messa et al.   ACTA HAEMATOLOGICA

Overexpression of Cellular Iron Import Proteins Is Associated with Malignant Progression of Esophageal Adenocarcinoma

(2008) J. Boult et al.   CLINICAL CANCER RESEARCH

Effect of Food, Type of Food, and Time of Food Intake on Deferasirox Bioavailability: Recommendations for an Optimal Deferasirox Administration Regimen

(2008) Renzo Galanello et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Donation Frequency, Iron Loss, and Risk of Cancer Among Blood Donors

(2008) Gustaf Edgren et al.   JNCI-Journal of the National Cancer Institute

Decreased Cancer Risk After Iron Reduction in Patients With Peripheral Arterial Disease: Results From a Randomized Trial

(2008) L. R. Zacharski et al.   JNCI-Journal of the National Cancer Institute